NASDAQ: VBIV - VBI Vaccines Inc.

Rentabilität für sechs Monate: -95.92%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan VBI Vaccines Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen VBI Vaccines Inc.

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

weitere details
In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1995-08-18
ISIN CA91822J1030
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.25
Сайт https://www.vbivaccines.com
Цена ао 0.58
Preisänderung pro Tag: 0% (0.0282)
Preisänderung pro Woche: 0% (0.0282)
Preisänderung pro Monat: 0% (0.0282)
Preisänderung über 3 Monate: 0% (0.0282)
Preisänderung über sechs Monate: -95.92% (0.692)
Preisänderung pro Jahr: -95.22% (0.59)
Preisänderung über 3 Jahre: -98.87% (2.49)
Preisänderung über 5 Jahre: -95.6% (0.6405)
Preisänderung über 10 Jahre: 0% (0.0282)
Preisänderung seit Jahresbeginn: 0% (0.0282)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0.9865 9
P/BV 1.14 9
P/E 0 0
EV/EBITDA -0.7112 0
Gesamt: 6

Effizienz

Name Bedeutung Grad
ROA, % -106.77 0
ROE, % -1233.37 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0.7 7
Gesamt: 1.16

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.9947 10
Gesamt: 8.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 294.64 10
Rentabilität Ebitda, % 15.66 3
Rentabilität EPS, % -60.52 0
Gesamt: 4.6
Weitere Details

Institutionen Volumen Aktie, %
Perceptive Advisors LLC 1381355 5.83
Alyeska Investment Group, L.P. 696736 2.94
Geode Capital Management, LLC 138729 0.59
Blackrock Inc. 111960 0.47
Cambridge Investment Research Advisors Inc. 93556 0.39
Millennium Management LLC 71422 0.3
Vanguard Group Inc 64522 0.27
General American Investors Company Inc 62583 0.26
Morgan Stanley 34973 0.15
Northern Trust Corporation 32992 0.14



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Jeffery R. Baxter FCMA President, CEO & Director 908.06k 1961 (64 Jahr)
Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D. Chief Medical Officer 544.52k 1955 (70 Jahre)
Ms. Nell Beattie CFO, Head of Corporate Development & Director N/A 1988 (37 Jahre)
Ms. Athena Kartsaklis Senior VP of Finance, Chief Compliance Officer & Principal Financial Officer N/A 1965 (60 Jahre)
Mr. Avi Mazaltov Global Head of Manufacturing & GM of SciVac N/A 1962 (63 Jahr)
Mr. Misha Nossov Senior VP of Global Commercial Supply Strategy & Head of Europe N/A
Mr. John Robert Dillman Chief Commercial Officer N/A 1968 (57 Jahre)
Dr. David Evander Anderson Ph.D. Chief Scientific Officer 1970 (55 Jahre)
Ms. Nicole Anderson Director of Corporate Communications & Investor Relations
Mr. T. Adam Buckley B.Sc., MBA Senior Vice President of Business Development 1976 (49 Jahre)

Adresse: United States, Cambridge. MA, 160 Second Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.vbivaccines.com